Page last updated: 2024-12-04

n'-formylkynurenine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

N'-formylkynurenine: a photochemical breakdown product of tryptophan in proteins; RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID439788
CHEMBL ID3577708
CHEBI ID30249
SCHEMBL ID145723
MeSH IDM0051152

Synonyms (29)

Synonym
n'-formylkynurenine
CHEBI:30249
3-(2-formamidobenzoyl)-l-alanine
(2s)-2-amino-4-(2-formamidophenyl)-4-oxobutanoic acid
nsc-334199
3978-11-8
kynurenine, n'-formyl-
formylkynurenine
C02700
l-formylkynurenine
(s)-2-amino-4-(2-formamidophenyl)-4-oxobutanoic acid
SCHEMBL145723
n'-formyl-l-kynurenine
CHEMBL3577708
(s)-2-amino-4-(2-formamidophenyl)-4-oxobutanoicacid
(2s)-2-amino-4-[2-(formylamino)phenyl]-4-oxobutanoic acid
benzenebutanoic acid, alpha-amino-2-(formylamino)-gamma-oxo-, (alphas)-
nsc 334199
unii-ps20w0733s
Q27104120
BYHJHXPTQMMKCA-QMMMGPOBSA-N
(2s)-2-amino-4-(2-(formylamino)phenyl)-4-oxobutanoic acid
n-acetyltryptophan impurity e [ep impurity]
benzenebutanoic acid, .alpha.-amino-2-(formylamino)-.gamma.-oxo-, (.alpha.s)-
tryptophan impurity e [ep impurity]
PS20W0733S ,
formylkynurenine, (s)-
n-formylkynurenine [ep impurity]
formyl-l-kynurenine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
N-formylkynurenine
non-proteinogenic L-alpha-amino acidAny L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
non-proteinogenic amino acid derivativeAny derivative of a non-proteinogenic amino acid resulting from reaction at an amino group or carboxy group, or from the replacement of any hydrogen by a heteroatom.
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Tryptophan degradation ( Tryptophan degradation )6454
NAD biosynthesis II (from tryptophan)024
tryptophan degradation I (via anthranilate)09
tryptophan degradation via kynurenine016
NAD biosynthesis (from tryptophan)020

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1226028Activity of recombinant human IDO assessed as retention time treated with L-Trp by HPLC analysis2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
N (1)-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (77)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (16.88)18.7374
1990's11 (14.29)18.2507
2000's14 (18.18)29.6817
2010's36 (46.75)24.3611
2020's3 (3.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (7.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other76 (92.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]